Iterum Operating Margin from 2010 to 2026
| ITRM Stock | USD 0.21 0.01 4.55% |
Check Iterum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iterum Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 493 K, Interest Income of 1 M or Depreciation And Amortization of 242.8 K, as well as many indicators such as Price To Sales Ratio of 1.8 K, Dividend Yield of 0.0 or Days Sales Outstanding of 10.4 K. Iterum financial statements analysis is a perfect complement when working with Iterum Therapeutics Valuation or Volatility modules.
Iterum | Operating Margin | Build AI portfolio with Iterum Stock |
Evaluating Iterum Therapeutics's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Iterum Therapeutics PLC's fundamental strength.
Latest Iterum Therapeutics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Iterum Therapeutics PLC over the last few years. It is Iterum Therapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iterum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (19.82) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Iterum Operating Margin Regression Statistics
| Arithmetic Mean | (1,369) | |
| Coefficient Of Variation | (104.72) | |
| Mean Deviation | 1,385 | |
| Median | (88.10) | |
| Standard Deviation | 1,434 | |
| Sample Variance | 2.1M | |
| Range | 3.1K | |
| R-Value | (0.88) | |
| Mean Square Error | 489,808 | |
| R-Squared | 0.78 | |
| Slope | (250.27) | |
| Total Sum of Squares | 32.9M |
Iterum Operating Margin History
About Iterum Therapeutics Financial Statements
Iterum Therapeutics investors utilize fundamental indicators, such as Operating Margin, to predict how Iterum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Iterum Therapeutics Correlation against competitors. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Pharmaceuticals sector continue expanding? Could Iterum diversify its offerings? Factors like these will boost the valuation of Iterum Therapeutics. Market participants price Iterum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iterum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.72) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Iterum Therapeutics PLC requires distinguishing between market price and book value, where the latter reflects Iterum's accounting equity. The concept of intrinsic value - what Iterum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Iterum Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iterum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.